journal article·2021-10-08

Fluorinated Polymeric Surfactant with a Pluronic-like Structure and Its Application as a Drug Carrier

Binxiao Wei, Yutao Cui, Shouchun Ma, Yu Wang, Xiang Guo, Jinwu Xiao, Wei Li, Aimin Pang, Yongping Bai

ACS Applied Polymer Materials· Volume 3· Issue 10
Publisher page

Abstract

Pluronics (PEO-PPO-PEO or PPO-PEO-PPO), as the first commercially used polymeric surfactants, designed and manufactured by BASF, have been applied in the development of many pharmaceutical formulations and drug load as well as delivery. Herein, the Williamson ether synthesis reaction was used to prepare hydrophobic monomer fluorinated epichlorohydrin (EPTF) considered as an intermediate state before. In addition, ABA triblock amphiphilic polymers (molecular weight ranging from 2083 to 8888 g/mol with the polymer dispersity index (PDI) lower than 1.52) with a Pluronic-like structure were synthesized by the living cationic polymerization of polyethylene oxide (PEO) and EPTF. The structures of EPTF and polymeric surfactants were characterized by Fourier infrared transform spectroscopy (FI-IR), nuclear magnetic resonance (NMR), and gel permeation chromatography (GPC). Moreover, these kinds of polymeric surfactants can not only reduce the surface tension of water but also self-assemble in water to form micelles with a much lower critical micelle concentration (CMC) ranging from 8.13 × 10–5 to 1.95 × 10–3 g/L. Baicalin, low-water-solubility anticancer drug, can be loaded into this polymeric surfactant to form nanomicelles by a solvent evaporation method. The particle size, colloidal stability, and loaded content were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and ultraviolet–visible (UV–vis) spectrometry. These results indicate that hydrophobic anticancer drugs, like baicalin, can be loaded into these kinds of surfactants with a much higher concentration (maximum 380.776 μg/mL) and excellent storage stability, overcoming their low water solubility so as to increase their therapeutic efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Polymer Synthesis and Characterization · Surfactants and Colloidal Systems · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

MIIT Key Laboratory of Critical Materials Technology for New Energy Conversion and Storage, School of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, Heilongjiang Province 150001, China

Jiangxi Bluestar Xinghuo Silicone Co., Ltd., Yongxiu County Xinghuo Industrial Park, Jiujiang, Jiangxi Province 330319, China

Science and Technology on Aerospace Chemical Power Laboratory, Hubei Institute of Aerospace Chemotechnology, Xiangyang, Hubei Province 441003, China

Wuxi HIT New Material Research Institute Co., Ltd., Wuxi, Jiangsu Province 214183, China

References (51)

Show source-provided references
1. 10.1002/slct.20190116010.1002/slct.201901160 ↗
2. 10.1016/j.foodchem.2021.12900310.1016/j.foodchem.2021.129003 ↗
3. 10.1002/marc.20030004810.1002/marc.200300048 ↗
4. Storsberg J. · SÖFW-J. · 2004 · 130 · 14
5. 10.1021/acs.macromol.9b0051910.1021/acs.macromol.9b00519 ↗
6. 10.1021/ma071285410.1021/ma0712854 ↗
7. 10.1021/cr500129h10.1021/cr500129h ↗
8. 10.1002/pola.2649410.1002/pola.26494 ↗
9. 10.1021/acsami.9b1596410.1021/acsami.9b15964 ↗
10. 10.1007/s10853-019-04296-910.1007/s10853-019-04296-9 ↗
11. 10.1002/anie.20201344310.1002/anie.202013443 ↗
12. 10.1021/ma200626p10.1021/ma200626p ↗
13. 10.1021/acs.macromol.0c0262810.1021/acs.macromol.0c02628 ↗
14. 10.1016/j.chemphys.2019.11046210.1016/j.chemphys.2019.110462 ↗
15. 10.1097/ALN.0b013e31818630ff10.1097/ALN.0b013e31818630ff ↗
16. 10.15171/apb.2017.04110.15171/apb.2017.041 ↗
17. Goddard E. · J. Colloid Interface Sci. · 2004 · 68 · 347
18. 10.1007/s00396-020-04631-610.1007/s00396-020-04631-6 ↗
19. Kabanov; Alexander, V. Amphiphilic Block Copolymers: Micelles of Amphiphilic Block Copolymers as Vehicles for Drug Delivery; Elsevier Press, 2000; pp 347–376.10.1016/B978-044482441-7/50016-5 ↗
20. 10.1016/j.jsps.2011.04.00110.1016/j.jsps.2011.04.001 ↗
21. 10.1248/cpb.49.144410.1248/cpb.49.1444 ↗
22. 10.1177/088391150606320710.1177/0883911506063207 ↗
23. 10.1016/j.jconrel.2011.08.01310.1016/j.jconrel.2011.08.013 ↗
24. 10.1021/mp500298q10.1021/mp500298q ↗
25. 10.1021/acs.jmedchem.7b0145710.1021/acs.jmedchem.7b01457 ↗
26. 10.1016/j.jconrel.2005.03.01910.1016/j.jconrel.2005.03.019 ↗
27. 10.1016/j.chemphyslip.2020.10497810.1016/j.chemphyslip.2020.104978 ↗
28. 10.2147/DDDT.S20145310.2147/DDDT.S201453 ↗
29. Sarfraz R. M. · Acta Pol. Pharm. · 2017 · 74 · 347
30. 10.1016/j.biomaterials.2018.08.02310.1016/j.biomaterials.2018.08.023 ↗
31. 10.1021/acsami.5b1154510.1021/acsami.5b11545 ↗
32. 10.1002/ange.20150146110.1002/ange.201501461 ↗
33. 10.1021/es070895g10.1021/es070895g ↗
34. 10.1021/acssuschemeng.9b0210510.1021/acssuschemeng.9b02105 ↗
35. 10.1021/jacs.6b1015010.1021/jacs.6b10150 ↗
36. 10.1021/ma801422c10.1021/ma801422c ↗
37. 10.1002/ange.20201341910.1002/ange.202013419 ↗
38. 10.3390/pharmaceutics1304043510.3390/pharmaceutics13040435 ↗
39. 10.1016/j.microc.2021.10597810.1016/j.microc.2021.105978 ↗
40. 10.1016/j.jfluchem.2016.09.00110.1016/j.jfluchem.2016.09.001 ↗
41. 10.1016/j.polymer.2013.01.04210.1016/j.polymer.2013.01.042 ↗
42. 10.1002/mren.20110002610.1002/mren.201100026 ↗
43. 10.1021/ma900795f10.1021/ma900795f ↗
44. 10.1021/ma970098a10.1021/ma970098a ↗
45. 10.1021/ma902725710.1021/ma9027257 ↗
46. 10.1002/pola.2307710.1002/pola.23077 ↗
47. 10.1021/la060192x10.1021/la060192x ↗
48. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
49. 10.1016/j.eurpolymj.2018.12.00510.1016/j.eurpolymj.2018.12.005 ↗
50. 10.1016/S0079-6700(03)00015-710.1016/S0079-6700(03)00015-7 ↗
51. 10.1039/D0SM02058C10.1039/D0SM02058C ↗